Related Experiment Video
Updated: Jul 17, 2026

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
Bactericidal activity and resistance development profiling of dalbavancin
Beth P Goldstein1, Deborah C Draghi, Daniel J Sheehan
1Pfizer Inc., Pfizer Global Pharmaceuticals, King of Prussia, PA, USA.
Abstract:
Dalbavancin, a semisynthetic lipoglycopeptide being developed for the treatment of skin and skin structure infections (SSSIs), has a half-life of 5 to 7 days in humans and offers promise for a convenient weekly dosing regimen. We studied the in vitro bactericidal activity of dalbavancin against target organisms, using the concentrations that are maintained in human blood with the proposed dosage regimen. Dalbavancin minimal bactericidal concentrations (MBCs) were
Related Concept Videos
Development of Antibiotic Resistance
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Antimicrobial Effectiveness
Inhibitors of Gram-positive Cell Wall Synthesis
Regulation of Bacterial Virulence
